Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)

• Published in: European Heart Journal
• Main Authors: Faergeman, O, Kjekshus, J, Cook, T, Pyörälä, K, Wilhelmsen, L, Thorgeirsson, G, Pedersen, T R
• Other Authors: Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus, Denmark.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Oxford University Press 2010
• Subjects: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Calcium Channel Blockers; Cause of Death; Coronary Disease; Female; Finland; Follow-Up Studies; Humans; Iceland; Male; Middle Aged; Myocardial Revascularization; Prognosis; Scandinavia; Simvastatin; Survival Rate; Warfarin
• Online Access: http://hdl.handle.net/2336/93623; https://doi.org/10.1053/euhj.1998.1191

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field AIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo. Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy. There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries. Surgical and medical therapy varied importantly between countries. CONCLUSIONS: Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking. They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease.